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Background:  A low-dose, controlled-release combination of phentermine and topiramate (PHEN/TPM CR) was developed as a chronic therapy to 
effect clinically meaningful weight loss and improvements in cardiovascular risk factors.
Methods:  An initial 56-week double-blind, controlled trial was conducted with 2487 overweight and obese subjects with two or more weight-
related comorbidities; subjects were randomized 2:1:2 to treatment with placebo, PHEN/TPM CR 7.5/46, or PHEN/TPM CR 15/92 and provided a 
lifestyle intervention and treatment to standard of care. Eligible subjects at a subset of sites were enrolled in a second year of treatment maintaining 
randomization and blinding.
Results:  Subjects in the extension study (N=675) had comparable baseline demographics to the originally randomized population: age 51 
years, 70% female, 86% Caucasian, BMI 36 kg/m2, blood pressure 128/80. 51% were hypertensive and 22% were diabetic at baseline. LS mean 
weight loss at 56 weeks was 1.2, 7.8 and 9.8% for placebo, 7.5/46 and 15/92, respectively; and at 108 weeks was 1.8, 9.3 and 10.5% (ITT-LOCF, 
P<0.0001). Blood pressure decreased in hypertensive subjects over the 108 weeks in all three groups, -6.7, -6.9 and -8.6 mmHg systolic, and -5.7, 
-4.8 and -5.8 mmHg diastolic, respectively, with placebo subjects requiring additional antihypertensive medications compared to PHEN/TPM CR 
treated subjects. In dyslipidemic patients HDL (9.1, 11.4 and 16.7%; ITT-LOCF, 15/92 P<0.015) and triglycerides (-14.3, -25.9 and -26.3%; ITT-LOCF, 
P=0.055 and 0.015) showed improvement over the full treatment period. The most common adverse events were sinusitis, dry mouth, paresthesia, 
constipation and dysgeusia.
Conclusion: Treatment with PHEN/TPM CR produced and maintained significant weight loss and improvements in cardiovascular risk factors in 
a comorbid population of overweight and obese subjects, and led to a reduction in the number of concomitant medications. PHEN/TPM CR was 
generally well tolerated over two years of treatment. Chronic therapies, such as PHEN/TPM CR, leading to sustained weight loss and improvements in 
weight-related comorbidities are needed to address the current epidemic of obesity.
